![Henry R. Wolfe](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Henry R. Wolfe
Nessuna posizione attualmente
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
George C. Prendergast | M | - |
Thomas Jefferson University
| 18 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Roy C. Levitt | M | 70 |
Genaera Corp.
![]() Genaera Corp. Pharmaceuticals: MajorHealth Technology Genaera Corp. develops drugs for asthma, cancer, cystic fibrosis and age-related macular degeneration. It is a biopharmaceutical company committed to developing medicines for serious diseases from genomics and natural products. It's products include EVIZON, to treat ophthalmic indications, specifically age-related macular degeneration. Squalamine lactate, for the treatment of cancerous solid tumors. It's third product candidate, LOMUCIN to treat the overproduction of mucus secretions involved in chronic respiratory disease. Fourth product candidate, interleukin-9 antibody, is a respiratory treatment based on the discovery of a genetic cause of asthma. It also has a number of discovery research programs focused on the treatment of obesity, infectious diseases and inflammatory disorders. The company is headquartered in Plymouth Meeting, PA. | 5 anni |
John L. Armstrong | M | 80 |
Genaera Corp.
![]() Genaera Corp. Pharmaceuticals: MajorHealth Technology Genaera Corp. develops drugs for asthma, cancer, cystic fibrosis and age-related macular degeneration. It is a biopharmaceutical company committed to developing medicines for serious diseases from genomics and natural products. It's products include EVIZON, to treat ophthalmic indications, specifically age-related macular degeneration. Squalamine lactate, for the treatment of cancerous solid tumors. It's third product candidate, LOMUCIN to treat the overproduction of mucus secretions involved in chronic respiratory disease. Fourth product candidate, interleukin-9 antibody, is a respiratory treatment based on the discovery of a genetic cause of asthma. It also has a number of discovery research programs focused on the treatment of obesity, infectious diseases and inflammatory disorders. The company is headquartered in Plymouth Meeting, PA. | 4 anni |
John A. Skolas | M | 71 |
Genaera Corp.
![]() Genaera Corp. Pharmaceuticals: MajorHealth Technology Genaera Corp. develops drugs for asthma, cancer, cystic fibrosis and age-related macular degeneration. It is a biopharmaceutical company committed to developing medicines for serious diseases from genomics and natural products. It's products include EVIZON, to treat ophthalmic indications, specifically age-related macular degeneration. Squalamine lactate, for the treatment of cancerous solid tumors. It's third product candidate, LOMUCIN to treat the overproduction of mucus secretions involved in chronic respiratory disease. Fourth product candidate, interleukin-9 antibody, is a respiratory treatment based on the discovery of a genetic cause of asthma. It also has a number of discovery research programs focused on the treatment of obesity, infectious diseases and inflammatory disorders. The company is headquartered in Plymouth Meeting, PA. | 4 anni |
Robert Barchi | M | 77 |
Thomas Jefferson University
| 8 anni |
Paul Wotton | M | 63 |
Genaera Corp.
![]() Genaera Corp. Pharmaceuticals: MajorHealth Technology Genaera Corp. develops drugs for asthma, cancer, cystic fibrosis and age-related macular degeneration. It is a biopharmaceutical company committed to developing medicines for serious diseases from genomics and natural products. It's products include EVIZON, to treat ophthalmic indications, specifically age-related macular degeneration. Squalamine lactate, for the treatment of cancerous solid tumors. It's third product candidate, LOMUCIN to treat the overproduction of mucus secretions involved in chronic respiratory disease. Fourth product candidate, interleukin-9 antibody, is a respiratory treatment based on the discovery of a genetic cause of asthma. It also has a number of discovery research programs focused on the treatment of obesity, infectious diseases and inflammatory disorders. The company is headquartered in Plymouth Meeting, PA. | 1 anni |
Richard Gozon | M | 85 |
Thomas Jefferson University
| 10 anni |
David D. Gathman | M | 76 |
Targeted Diagnostics & Therapeutics, Inc.
![]() Targeted Diagnostics & Therapeutics, Inc. Medical SpecialtiesHealth Technology Targeted Diagnostics & Therapeutics, Inc. operates as a biotechnology company. The firm develops molecular diagnostics and therapeutics for the diagnosis and treatment of colorectal cancer and other gastrointestinal diseases. Its activities include research and development projects in in-vitro diagnostics and imaging agents, receptor-based therapeutics, and cancer vaccines; and a clinical laboratory for testing blood and tissues for metastatic colorectal cancer for patients. The company was founded by Harry A. Arena in August 1994 and is headquartered in West Chester, PA. | 1 anni |
Mitchell Kaye | M | 56 |
Genaera Corp.
![]() Genaera Corp. Pharmaceuticals: MajorHealth Technology Genaera Corp. develops drugs for asthma, cancer, cystic fibrosis and age-related macular degeneration. It is a biopharmaceutical company committed to developing medicines for serious diseases from genomics and natural products. It's products include EVIZON, to treat ophthalmic indications, specifically age-related macular degeneration. Squalamine lactate, for the treatment of cancerous solid tumors. It's third product candidate, LOMUCIN to treat the overproduction of mucus secretions involved in chronic respiratory disease. Fourth product candidate, interleukin-9 antibody, is a respiratory treatment based on the discovery of a genetic cause of asthma. It also has a number of discovery research programs focused on the treatment of obesity, infectious diseases and inflammatory disorders. The company is headquartered in Plymouth Meeting, PA. | 2 anni |
Peter J. Savino | M | 81 |
Genaera Corp.
![]() Genaera Corp. Pharmaceuticals: MajorHealth Technology Genaera Corp. develops drugs for asthma, cancer, cystic fibrosis and age-related macular degeneration. It is a biopharmaceutical company committed to developing medicines for serious diseases from genomics and natural products. It's products include EVIZON, to treat ophthalmic indications, specifically age-related macular degeneration. Squalamine lactate, for the treatment of cancerous solid tumors. It's third product candidate, LOMUCIN to treat the overproduction of mucus secretions involved in chronic respiratory disease. Fourth product candidate, interleukin-9 antibody, is a respiratory treatment based on the discovery of a genetic cause of asthma. It also has a number of discovery research programs focused on the treatment of obesity, infectious diseases and inflammatory disorders. The company is headquartered in Plymouth Meeting, PA. | - |
Randy Burd | M | - |
Thomas Jefferson University
| 2 anni |
Luke Sergott | M | - |
Thomas Jefferson University
| 2 anni |
Eugene Kennedy | M | 55 |
Thomas Jefferson University
| 7 anni |
Richard G. Pestell | M | - |
Thomas Jefferson University
| 11 anni |
Justin Young | M | - |
Thomas Jefferson University
| 3 anni |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Stati Uniti | 15 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Henry R. Wolfe
- Contatti personali